Figure 5.

Nuclear CyKILRa acts as a tumor suppressing factor

The depicted cell lines were transfected with SCR ASO or CyKILRa ASO (ASO). After 48 h, total RNA was extracted or in concomitant experiments, the cells were assessed for the indicated biological mechanisms with the 48 h after transfection acting as the 0 time point (A–D). In addition, 48 h post-transfected H2009 and H1792 cells were subsequently mixed with Matrigel in a 1:1 ratio and injected sc into the flanks of 5-week-old female NOD-SCID mice (1 × 10⁶ cells per mouse per flank). The left flank received control-treated cells, while the right flank received knockdown cells (E). (A) RNA levels of CyKILRa in the depicted cell lines after ASO treatment normalized to the mRNA levels of GAPDH. −RT controls were included in all experiments and replicates with no signal observed. (B) Proliferation of CyKILRa ASO-treated cells compared with SCR ASO-treated cells at the 48-h time point. (C) Migration of CyKILRa ASO-treated samples compared with SCR ASO-treated cells at the 24-h time point. (D) Plate clonogenic survival of CyKILRa ASO-treated cells compared with SCR ASO-treated cells. (E) Tumor volume of ASO-Con or CyKILRa ASO treated H2009 or H1792 in mice. The data are presented as boxplots (n ≥ 3 replicates), and statistical analysis was performed using the unpaired t test with Welch’s correction.